Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 26;9:2189. doi: 10.3389/fimmu.2018.02189

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Mike, Makinde, Der, Stock, Gulinello, Gadhvi, Winter, Cuda and Putterman.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Fingolimod reduces splenomegaly, lymphadenopathy, and serum autoantibodies. (A,B) Spleens (A) and lymph nodes (B) from treated and control mice were weighed and corrected for body weight. Representative images of spleens (A) and lymph nodes (B) from control and treated mice are shown. Control treated, n = 7–16; Fingolimod treated, n = 7–16. (C) Antibodies to double stranded DNA and chromatin were assessed in serum from control and treated mice collected after 10 weeks of treatment (e.g., at 20 weeks of age). Data were normalized and are shown as a percentage of positive control. Control treated, n = 16; Fingolimod treated, n = 16. ^*p < 0.05, ^**p < 0.01, ^****p < 0.0001. Results are displayed as mean ± SEM.